Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Grifols, S.A. GRF.MC
$11.11
+$0.09 (0.82%)
На 18:04, 12 мая 2023
Ранг: 2
Ключевые показатели
-
Marketcap
6333390599.00000000
-
week52high
20.28
-
week52low
7.82
-
Revenue
6063967000
-
P/E TTM
31
-
Beta
0.42977000
-
EPS
0.30000000
-
Last Dividend
2.86237600
-
Next Earnings Date
09 мая 2023 г. в 06:30
Описание компании
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases. It offers immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division offers non-biological pharmaceutical products and medical supplies clinical nutrition, intravenous therapy, and medical devices. The Diagnostic division researches, develops, produces, and commercializes diagnostic products that span the healthcare continuum–from prevention, screening, diagnosis, and prognosis to disease and treatment monitoring–to serve professionals. The Bio Supplies division provides biological materials for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.
Рекомендации
аналитиков
Рекомендации аналитиков
Grading company | New grade | Previous grade | Recommendation date |
---|---|---|---|
Credit Suisse | Outperform | Neutral | 23 мар 2021 г. |
HSBC | Buy | Hold | 11 мар 2021 г. |
Santander | Buy | Hold | 28 окт 2019 г. |
JP Morgan | Overweight | Neutral | 27 июн 2019 г. |
Morgan Stanley | Underweight | Underweight | 02 янв 2019 г. |
Deutsche Bank | Hold | Buy | 05 ноя 2021 г. |
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Свежие комментарии
Свежие комментарии